Get the latest news, insights, and market updates on CVRX (CVRx, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates
CVRx (CVRX) delivered earnings and revenue surprises of -9.62% and +0.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock? Aug 4, 2025 - $CVRX
CVRx: Q2 Earnings Snapshot
MINNEAPOLIS (AP) — CVRx Inc. CVRX) on Monday reported a loss of $14.7 million in its second quarter. On a per-share basis, the Minneapolis-based company said it had a loss of 57 cents. Aug 4, 2025 - $CVRX
CVRx Reports Second Quarter 2025 Financial and Operating Results
MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2025. Recent Highlights Total revenue for the second quarter 2025 was $13.6 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) reven Aug 4, 2025 - $CVRX
CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference
MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 3:00pm Eastern Time the same day via webcast. A live audio we Jul 29, 2025 - $CVRX
CVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025
MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2025 financial and operating results after market close on Monday, August 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.A Jul 21, 2025 - $CVRX
CVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains?
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. Jul 17, 2025 - $CVRX
CVRx Announces Positive News on Outpatient Payment for Barostim
MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim implant procedure as part of the New Technology Ambulatory Payment Classification (APC) 1580, with an associated payment of approximately $45,000 for procedures performed in the outpatient setting. CMS is also soliciting comments about the need for a Level 6 Neurost Jul 16, 2025 - $CVRX
CVRx to Present at the William Blair 45th Annual Growth Stock Conference
MINNEAPOLIS, May 28, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025. The Company is scheduled to present at 10:00am Central Time the same day via webcast. A live audio w May 28, 2025 - $CVRX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple